Study summary
Sedatives-SAVE-ICU is a retrospective cohort study comparing the use analgesic, sedative, and antipsychotic medications among participants of the SAVE-ICU. SAVE-ICU RCT introduced a novel mode of sedation using inhaled agents. These agents can be opioid and sedative sparing. However, adherence to standard of care and novelty of inhaled sedatives may lead to adjunct use of analgesics, IV sedatives and antipsychotics in the intervention arm of the SAVE-ICU trial. Furthermore, given that COVID-19 patients may have higher sedation needs, the use of adjunct analgesics, IV sedatives and antipsychotics in the intervention group maybe more prevalent among COVID-19 participants. The aim of Sedatives-SAVE-ICU retrospective study is to compare the use of use analgesic, sedative, and antipsychotic medications between two arms of the SAVE-ICU trial and provide early indication whether adjunct use of these medications may impact clinical outcomes of the SAVE-ICU trial (ventilator- and ICU- free days). The study’s primary objective is to determine if there is difference in the cumulative dose of opioids between the intervention and control arms of the SAVE-ICU trial. Secondary objectives are to determine if patients in the inhaled sedation arm of the SAVE-ICU trial receive lower cumulative dose of benzodiazepines, non-opioid analgesics, or antipsychotic medications, and whether COVID-19 patients require higher doses of opioids, sedatives, benzodiazepines, non-opioid analgesics, or antipsychotic medications compared to non-COVID patients in both intervention and control arms of the SAVE-ICU trial
Team List
Study publications
Coming soon
